Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

Literature DB >> 2840017

Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

F G Araujo¹, D R Guptill, J S Remington.

Abstract

Doses of 200 mg of azithromycin per kg (body weight) administered by the oral route daily for 10 days completely protected mice against death caused by intraperitoneal infection with Toxoplasma gondii. The same treatment regimen also protected 80% of mice infected intracerebrally, which suggests that azithromycin attains active concentrations in the inflamed central nervous system.

Entities: Chemical Disease Species

Mesh：

Substances：
Erythromycin
Azithromycin

Year: 1988 PMID： 2840017 PMCID： PMC172266 DOI： 10.1128/AAC.32.5.755

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

9 in total

1. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.

Authors: M Walsh; E W Kappus; T C Quinn
Journal: Antimicrob Agents Chemother Date: 1987-05 Impact factor: 5.191

Review 2. Inhibition of folate biosynthesis and function as a basis for chemotherapy.

Authors: G H Hitchings; J J Burchall
Journal: Adv Enzymol Relat Areas Mol Biol Date: 1965

3. [Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women].

Authors: J P Garin; J Pellerat; R Woehrle
Journal: Presse Med Date: 1968-12-07 Impact factor: 1.228

4. Toxoplasmosis in immunocompromised patients.

Authors: F G Araujo; J S Remington
Journal: Eur J Clin Microbiol Date: 1987-02 Impact factor: 3.267

5. Effect of clindamycin on acute and chronic toxoplasmosis in mice.

Authors: F G Araujo; J S Remington
Journal: Antimicrob Agents Chemother Date: 1974-06 Impact factor: 5.191

6. Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

Authors: J Chan; B J Luft
Journal: Antimicrob Agents Chemother Date: 1986-08 Impact factor: 5.191

Review 7. Toxoplasmosis in the compromised host.

Authors: J Ruskin; J S Remington
Journal: Ann Intern Med Date: 1976-02 Impact factor: 25.391

8. Murine model of intracerebral toxoplasmosis.

Authors: J M Hofflin; F K Conley; J S Remington
Journal: J Infect Dis Date: 1987-03 Impact factor: 5.226

9. Effect of roxithromycin on acute toxoplasmosis in mice.

Authors: H R Chang; J C Pechere
Journal: Antimicrob Agents Chemother Date: 1987-07 Impact factor: 5.191

9 in total

36 in total

1. Quinupristin-dalfopristin is active against Toxoplasma gondii.

Authors: A A Khan; T R Slifer; F G Araujo; J S Remington
Journal: Antimicrob Agents Chemother Date: 1999-08 Impact factor: 5.191

2. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

Authors: S K Moshkani; A Dalimi
Journal: Vet Res Commun Date: 2000-04 Impact factor: 2.459

Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii.

1. In vitro evaluation of CP-62,993, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis.

Review 2. Inhibition of folate biosynthesis and function as a basis for chemotherapy.

3. [Theoretical bases of the prevention by spiramycin of congenital toxoplasmosis in pregnant women].

4. Toxoplasmosis in immunocompromised patients.

5. Effect of clindamycin on acute and chronic toxoplasmosis in mice.

6. Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.

Review 7. Toxoplasmosis in the compromised host.

8. Murine model of intracerebral toxoplasmosis.

9. Effect of roxithromycin on acute toxoplasmosis in mice.

1. Quinupristin-dalfopristin is active against Toxoplasma gondii.

2. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.

Review 3. New directions for macrolide antibiotics: structural modifications and in vitro activity.

4. In vitro activity of azithromycin and dirithromycin against axenic Entamoeba histolytica.

Review 5. The activity of azithromycin in animal models of infection.

6. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye.

Review 7. The pharmacokinetics of azithromycin and their clinical significance.

Review 8. Spectrum of activity of azithromycin.

9. In vitro activity of azithromycin against clinical isolates of Legionella species.

10. In vitro and in vivo effects of doxycycline on Toxoplasma gondii.